Skip to main content
icon for ¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?

¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?

icon for ¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?

¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?

NUEVO
31 ago 2026
Polymarket

$0.00 Vol.

Polymarket

10,000+

$0 Vol.

83%

15,000+

$0 Vol.

35%

20,000+

$0 Vol.

25%

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.Recent CDC surveillance shows over 4,173 laboratory-confirmed domestic cyclosporiasis cases since May 1, 2026—far exceeding the prior year—with thousands more under investigation amid a multistate outbreak linked to contaminated iceberg lettuce. Cyclospora cayetanensis transmission peaks in warmer months via fecal-oral routes in produce, with symptoms including prolonged watery diarrhea; official case counts reflect confirmed infections only, while underreporting remains common. Trader focus centers on whether cumulative reports will surpass key thresholds by August 31, influenced by ongoing FDA tracebacks, state surveillance intensity, and any new contamination events before the typical seasonal decline. Updated CDC reports and model-adjusted projections for late-summer produce supply chains represent the next key data points.

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
Volumen
$0
Fecha de finalización
31 ago 2026
Mercado abierto
Jul 27, 2026, 11:16 PM ET
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.Recent CDC surveillance shows over 4,173 laboratory-confirmed domestic cyclosporiasis cases since May 1, 2026—far exceeding the prior year—with thousands more under investigation amid a multistate outbreak linked to contaminated iceberg lettuce. Cyclospora cayetanensis transmission peaks in warmer months via fecal-oral routes in produce, with symptoms including prolonged watery diarrhea; official case counts reflect confirmed infections only, while underreporting remains common. Trader focus centers on whether cumulative reports will surpass key thresholds by August 31, influenced by ongoing FDA tracebacks, state surveillance intensity, and any new contamination events before the typical seasonal decline. Updated CDC reports and model-adjusted projections for late-summer produce supply chains represent the next key data points.

This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used.

Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.
Volumen
$0
Fecha de finalización
31 ago 2026
Mercado abierto
Jul 27, 2026, 11:16 PM ET
This market will resolve to "Yes" if there have been the specified amount or more confirmed domestically acquired cases of cyclosporiasis in humans in the territory of the United States of America since May 1, 2026, according to the CDC surveillance count by August 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Surveillance of Cyclosporiasis page’s “U.S. cases reported to CDC” count (see: https://www.cdc.gov/cyclosporiasis/php/surveillance/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC as confirmed domestically acquired cases of cyclosporiasis will qualify, regardless of reports from U.S. State agencies or other sources. Travel-associated cases acquired outside the United States will not qualify.

Cuidado con los enlaces externos.

Preguntas frecuentes

"¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?" es un mercado de predicción en Polymarket con 3 resultados posibles donde los operadores compran y venden acciones según lo que creen que sucederá. El resultado líder actual es "10,000+" con 83%, seguido de "15,000+" con 35%. Los precios reflejan probabilidades en tiempo real de la comunidad. Por ejemplo, una acción cotizada a 83¢ implica que el mercado colectivamente asigna una probabilidad de 83% a ese resultado. Estas probabilidades cambian continuamente a medida que los operadores reaccionan a nuevos desarrollos. Las acciones del resultado correcto son canjeables por $1 cada una tras la resolución del mercado.

"¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?" es un mercado recién creado en Polymarket, lanzado el Jul 27, 2026. Como mercado nuevo, esta es tu oportunidad de ser uno de los primeros operadores en establecer las probabilidades y las señales de precio iniciales del mercado. También puedes guardar esta página en marcadores para seguir el volumen y la actividad de trading a medida que el mercado gana tracción.

Para operar en "¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?", explora los 3 resultados disponibles en esta página. Cada resultado muestra un precio actual que representa la probabilidad implícita del mercado. Para tomar una posición, selecciona el resultado que consideres más probable, elige "Sí" para operar a favor o "No" para operar en contra, introduce tu cantidad y haz clic en "Operar". Si tu resultado elegido es correcto cuando el mercado se resuelve, tus acciones de "Sí" pagan $1 cada una. Si es incorrecto, pagan $0. También puedes vender tus acciones en cualquier momento antes de la resolución.

El favorito actual para "¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?" es "10,000+" con 83%, lo que significa que el mercado asigna una probabilidad de 83% a ese resultado. El siguiente resultado más cercano es "15,000+" con 35%. Estas probabilidades se actualizan en tiempo real a medida que los operadores compran y venden acciones. Vuelve con frecuencia o guarda esta página en marcadores.

Las reglas de resolución para "¿Casos de ciclosporiasis en EE. UU. antes del 31 de agosto?" definen exactamente qué debe ocurrir para que cada resultado sea declarado ganador, incluyendo las fuentes de datos oficiales utilizadas para determinar el resultado. Puedes revisar los criterios de resolución completos en la sección "Reglas" en esta página sobre los comentarios. Recomendamos leer las reglas cuidadosamente antes de operar, ya que especifican las condiciones exactas, casos especiales y fuentes.